Pfizer gets palbo review date

Pfizer gets palbo review date
Pfizer gets palbo review date

Pfizer's breast cancer drug palbociclib has an FDA review date. The company announced Monday that the Breakthrough Therapy breast cancer drug will get a regulatory yea or nay by April 13, 2015. The experimental drug is being reviewed for postmenopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer who have not received previous systemic treatment.

The company's announcement is just two months after the August filing date it anticipated in its second-quarter earnings call. The drug is partly of note because it could be a foundational one were Pfizer to break up into three independent units after 2017.

close

Next Article in Pharmaceutical